PHATHOM PHARMACEUTICALS, INC. (PHAT) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $5.36M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value $384.91M; Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value (m); Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $5.36M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $5.36M |
| Deferred revenue · latest quarter (USD) | $384.91M | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. $37.28M + $347.63M ≈ $384.91M |
| Other obligations · due within 1 year (USD) | (m) | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due after 1 year (USD) | $3.50M | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. $3.50M − $0.00 ≈ $3.50M |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 671.35M USD | Liabilities |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Amounts owed to suppliers | 5.36M USD | Accounts Payable, Current |
| Total deferred revenue | 384.91M USD | Contract with Customer, Liability, Current · Contract with Customer, Liability, Noncurrent |
| Deferred revenue due within one year | 37.28M USD | Contract with Customer, Liability, Current |
| Deferred revenue due after one year | 347.63M USD | Contract with Customer, Liability, Noncurrent · Contract with Customer, Liability, Current |
| Reported other obligations due within one year | (m) | Other Liabilities, Current |
| Reported other noncurrent obligations | 3.50M USD | Other Liabilities, Noncurrent |
| Deferred revenue included in other noncurrent obligations | 0.00 USD | Contract with Customer, Liability, Current |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- (m)
- Other obligations · due after 1 year (USD)
- $3.50M
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $2.52M |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $5.36M | $384.91M | (m) | $3.50M | $671.35M | (m) | $37.28M | $347.63M | $3.50M | $0.00 |
| 2026-03-31 | (m) | $6.37M | $380.91M | (m) | $3.50M | $642.08M | (m) | $33.02M | $347.90M | $3.50M | $0.00 |
| 2025-12-31 | (m) | $4.98M | $377.37M | $7.50M | $4.00M | $697.32M | (m) | $27.25M | $350.12M | $4.00M | $0.00 |
| 2025-09-30 | (m) | $1.07M | $373.33M | (m) | $11.50M | $662.82M | (m) | $24.34M | $348.98M | $11.50M | $0.00 |
| 2025-06-30 | (m) | $4.01M | $368.53M | (m) | $11.50M | $656.05M | (m) | $21.53M | $347.00M | $11.50M | $0.00 |
| 2025-03-31 | (m) | $11.62M | $361.07M | (m) | $11.50M | $632.58M | (m) | $17.27M | $343.81M | $11.50M | $0.00 |
| 2024-12-31 | (m) | $10.51M | $353.04M | (m) | $11.50M | $631.90M | (m) | $19.78M | $333.26M | $11.50M | $0.00 |
| 2024-09-30 | (m) | $7.13M | $342.58M | (m) | $10.75M | $574.16M | (m) | $20.19M | $322.39M | $10.75M | $0.00 |
| 2024-06-30 | (m) | $7.66M | $331.10M | (m) | $10.45M | $553.21M | (m) | $9.91M | $321.19M | $10.45M | $0.00 |
| 2024-03-31 | (m) | $8.40M | $319.01M | (m) | $9.70M | $505.00M | (m) | $16.48M | $302.53M | $9.70M | $0.00 |
| 2023-12-31 | (m) | $12.60M | $306.93M | (m) | $9.70M | $486.60M | (m) | $7.11M | $299.82M | $9.70M | $0.00 |
| 2023-09-30 | (m) | $5.79M | $125.79M | (m) | $7.50M | $254.76M | (m) | $2.39M | $123.40M | $7.50M | $0.00 |
| 2023-06-30 | (m) | $4.17M | $120.08M | (m) | $7.50M | $247.44M | (m) | $276.00K | $119.80M | $7.50M | $0.00 |
| 2023-03-31 | (m) | $4.80M | (m) | (m) | (m) | $234.21M | (m) | (m) | (m) | $7.50M | (m) |
| 2022-12-31 | (m) | $10.00M | (m) | (m) | (m) | $239.62M | (m) | (m) | (m) | $7.50M | (m) |
| 2022-09-30 | (m) | $7.13M | (m) | (m) | (m) | $228.35M | (m) | (m) | (m) | $7.50M | (m) |
| 2022-06-30 | (m) | $5.76M | (m) | (m) | (m) | $220.50M | (m) | (m) | (m) | $7.50M | (m) |
| 2022-03-31 | (m) | $2.86M | (m) | (m) | (m) | $111.01M | (m) | (m) | (m) | $7.50M | (m) |
| 2021-12-31 | (m) | $5.15M | (m) | (m) | (m) | $117.28M | (m) | (m) | (m) | $7.50M | (m) |
| 2021-09-30 | (m) | $5.58M | (m) | (m) | (m) | $124.90M | (m) | (m) | (m) | $7.50M | (m) |
| 2021-06-30 | (m) | $5.40M | (m) | (m) | (m) | $82.45M | (m) | (m) | (m) | $4.13M | (m) |
| 2021-03-31 | (m) | $10.86M | (m) | (m) | (m) | $82.02M | (m) | (m) | (m) | $4.13M | (m) |
| 2020-12-31 | (m) | $16.78M | (m) | (m) | (m) | $100.84M | (m) | (m) | (m) | $4.13M | (m) |
| 2020-09-30 | (m) | $4.79M | (m) | (m) | (m) | $74.50M | (m) | (m) | (m) | $4.13M | (m) |
| 2020-06-30 | (m) | $4.89M | (m) | (m) | (m) | $64.00M | (m) | (m) | (m) | $4.13M | (m) |
| 2020-03-31 | (m) | $1.19M | (m) | (m) | (m) | $55.22M | (m) | (m) | (m) | $4.13M | (m) |
| 2019-12-31 | (m) | $699.00K | (m) | (m) | (m) | $29.22M | (m) | (m) | (m) | $2.06M | (m) |
| 2019-09-30 | (m) | $439.00K | (m) | (m) | (m) | $232.17M | (m) | (m) | (m) | $2.06M | (m) |
| 2018-12-31 | (m) | $55.00K | (m) | (m) | (m) | $2.19M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |